Status:
UNKNOWN
PhytoSERM for Menopausal Hot Flashes and Sustained Brain Health
Lead Sponsor:
NeuTherapeutics
Collaborating Sponsors:
University of Arizona
Conditions:
Menopause
Hot Flashes
Eligibility:
FEMALE
45-60 years
Phase:
PHASE2
Brief Summary
This is a proof-of-concept phase 2 clinical trial to investigate the effect of the phytoestrogenic supplement PhytoSERM on vasomotor symptoms and other symptoms associated with the menopausal transiti...
Detailed Description
This is a double-blinded, randomized, placebo-controlled, parallel designed, proof-of-concept phase 2 clinical trial to determine effect of PhytoSERM on vasomotor symptoms and other symptoms associate...
Eligibility Criteria
Inclusion
- Peri- or postmenopausal women, defined by any of the following:
- Last menstrual period (LMP) completed ≥ 60 days and ≤ 8 years, per the Stages of Reproductive Aging Workshop (STRAW) criteria.
- Post-hysterectomy or endometrial ablation ≥ 3 months and supported by FSH levels.
- Age 45-60 years.
- Presence of hot flashes ≥ 7 per day.
- Clinical laboratory values must be within normal limits or, if abnormal, must be judged to be not clinically significant by the investigator.
- Mammogram within normal limits in the past 2 years: Breast Imaging Reporting and Data System (BI-RADS) category 1-2 or 3 with findings stable for 3 years.
- No medical contraindications to study participation.
- Stable medications for 4 weeks prior to the baseline visits.
- Ability to take oral medication and be willing to adhere to the PhytoSERM regimen.
- For females of reproductive potential: Negative pregnancy test and use of highly effective contraception by male partner for at least 1 month prior to screening and agreement to use such a method during study participation.
Exclusion
- Use of isoflavone containing supplements.
- Known allergies to isoflavones or soy-based products.
- Montreal Cognitive Assessment total score \< 22.
- Pregnancy
- Use of estrogen or progestin compounds within 8 weeks of baseline.
- Use of investigational agent within 12 weeks of baseline.
- Concurrent neurologic, systemic, or psychiatric disease that would influence cognition or ability to provide informed consent and to participate.
- Known or suspected estrogen-dependent neoplasia (breast, ovarian and uterine cancers), active neoplastic disease, history of breast cancer, and endometrial hyperplasia.
- History within the last 5 years of any other primary or recurrent malignant disease, with the exception of resected cutaneous squamous cell carcinoma in situ, and basal cell carcinoma.
- History of epilepsy, focal brain lesion, head injury with loss of consciousness or DSM IV criteria for any major psychiatric disorder including psychosis, major depression, bipolar disorder, alcohol, or substance abuse.
- Thrombophlebitis, thrombosis, thromboembolic disorders, myocardial infarction, ischemic heart disease, cerebrovascular accident, stroke, TIA.
- Current use of tobacco or a history of alcohol abuse.
- Use of anticoagulants.
- Chronic use of most benzodiazepines
- Use of drugs, herbs, or dietary supplements to treat menopausal or cognitive symptoms less than 8 weeks prior to baseline (e.g., SSRIs, rhubarb, red clover, licorice, kudzu, black cohosh, ginseng or other similar roots, etc.)
- Evidence of any significant clinical disorder or laboratory finding, including clinically significant or unstable hematologic, hepatic, cardiovascular, pulmonary, gastrointestinal, endocrine, metabolic, renal, or other systemic disease or laboratory abnormality.
- Known allergy to soy-derived products/ proteins or branded over the counter products; hypersensitivity to estrogens or progestins.
Key Trial Info
Start Date :
November 17 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 15 2024
Estimated Enrollment :
132 Patients enrolled
Trial Details
Trial ID
NCT06186531
Start Date
November 17 2023
End Date
November 15 2024
Last Update
January 2 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Arizona
Tucson, Arizona, United States, 85724